http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019036720-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9fb7bbc09927d64558e1e99a3b7c719b |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09 |
| filingDate | 2018-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42afddae9170e0804a31f857b93cd30e |
| publicationDate | 2019-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2019036720-A1 |
| titleOfInvention | TARGETING MICROARN TO ENHANCE AUTOPHAGIC ACTIVITY IN MUCOVISCIDOSIS AND RELATED DISORDERS |
| abstract | The present invention relates to a treatment of cystic fibrosis and cystic fibrosis treatment compositions. The present invention also provides methods of modulating autophagy activity and compositions for modulating autophagy activity. In specific aspects, the present invention relates to antagomirs that comprise a nucleic acid that hybridizes to a Mir17-92 cluster under moderate or high stringency conditions. The present invention further relates to pharmaceutical compositions comprising these antagomirs and a pharmaceutically acceptable carrier. The present invention also relates to methods of using these pharmaceutical compositions to treat a patient with cystic fibrosis, increasing the disappearance of an infection in a patient with cystic fibrosis, reducing inflammation in a patient, modulating the activity of autophagy in a patient, increasing CFTR function in a patient, and treating other associated diseases. The present invention further relates to methods for evaluating expression levels of Mir17-92. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110468084-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-116334138-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023092151-A1 |
| priorityDate | 2017-08-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 101.